The global lenalidomide market size was estimated to be USD 10.74 billion in 2023 and is expected to reach USD 18.67 billion by 2034 with a CAGR of 5.16% during the forecast period 2024-2034. Rising incidence of hematological cancers, expanding applications, patent exclusivity and market competition, advancements in drug combinations, increasing awareness and diagnosis, government initiatives and healthcare policies, and technological advancements in drug delivery will drive market growth.
Hematological cancers including multiple myeloma and myelodysplastic syndromes are frequently treated with lenalidomide. The market for lenalidomide is expanding due in part to the rising incidence of these illnesses around the world. Research and clinical studies examining the use of lenalidomide in various hematological and non-hematological indications may drive market expansion. The medication's effectiveness under various circumstances may result in more approvals and more market demand. For instance, Mylan N.V. Received USFDA clearance for its generic lenalidomide capsules in 2023.
By type, the 10mg capsules segment accounted for the highest revenue-grossing segment in the global lenalidomide market in 2023 owing to the widespread adoption of this dosage strength for its optimal balance between therapeutic efficacy and manageable side effects, making it a preferred choice among healthcare professionals for the treatment of hematological malignancies such as multiple myeloma and myelodysplastic syndromes. For instance, Bristol Myers Squibb Received FDA clearance for lenalidomide in conjunction with rituximab for treatment of follicular lymphoma on January 10, 2023. Additionally, the 5mg capsules segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on personalized medicine and the trend toward individualized treatment plans in hematological disorders.
By application, the multiple myeloma segment accounted for the highest revenue-grossing segment in the global lenalidomide market in 2023 owing to the increasing prevalence of multiple myeloma worldwide and the consistent efficacy demonstrated by lenalidomide as a key component in the treatment regimens for this hematological malignancy. For instance, Dr. Reddy's Laboratories Ltd. Received US FDA clearance for their lenalidomide oral suspension on June 20, 2023. Additionally, the myelodysplastic syndromes segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of lenalidomide as an effective therapeutic option for addressing the specific needs of patients with myelodysplastic syndromes.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global lenalidomide market in 2023 owing to the crucial role that hospitals play as primary healthcare providers and treatment centers for complex hematological disorders. For instance, Novartis International AG announced the favorable Phase 3 study findings in February 2023 for lenalidomide with another medication for the treatment of multiple myeloma. Additionally, the cancer treatment centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on specialized facilities for comprehensive cancer care and the rising demand for targeted and personalized treatment approaches.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, increased prevalence of hematological disorders, and a robust regulatory framework facilitating the rapid adoption of lenalidomide. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of hematological disorders, a growing elderly population, and rising healthcare investments. For instance, Novartis International AG filed a regulatory application in November 2023 for lenalidomide plus another medication to treat multiple myeloma to gain quicker access to the market.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Hematological cancers including multiple myeloma and myelodysplastic syndromes are frequently treated with lenalidomide. The market for lenalidomide is expanding due in part to the rising incidence of these illnesses around the world. Research and clinical studies examining the use of lenalidomide in various hematological and non-hematological indications may drive market expansion. The medication's effectiveness under various circumstances may result in more approvals and more market demand. For instance, Mylan N.V. Received USFDA clearance for its generic lenalidomide capsules in 2023.
By type, the 10mg capsules segment accounted for the highest revenue-grossing segment in the global lenalidomide market in 2023 owing to the widespread adoption of this dosage strength for its optimal balance between therapeutic efficacy and manageable side effects, making it a preferred choice among healthcare professionals for the treatment of hematological malignancies such as multiple myeloma and myelodysplastic syndromes. For instance, Bristol Myers Squibb Received FDA clearance for lenalidomide in conjunction with rituximab for treatment of follicular lymphoma on January 10, 2023. Additionally, the 5mg capsules segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on personalized medicine and the trend toward individualized treatment plans in hematological disorders.
By application, the multiple myeloma segment accounted for the highest revenue-grossing segment in the global lenalidomide market in 2023 owing to the increasing prevalence of multiple myeloma worldwide and the consistent efficacy demonstrated by lenalidomide as a key component in the treatment regimens for this hematological malignancy. For instance, Dr. Reddy's Laboratories Ltd. Received US FDA clearance for their lenalidomide oral suspension on June 20, 2023. Additionally, the myelodysplastic syndromes segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of lenalidomide as an effective therapeutic option for addressing the specific needs of patients with myelodysplastic syndromes.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global lenalidomide market in 2023 owing to the crucial role that hospitals play as primary healthcare providers and treatment centers for complex hematological disorders. For instance, Novartis International AG announced the favorable Phase 3 study findings in February 2023 for lenalidomide with another medication for the treatment of multiple myeloma. Additionally, the cancer treatment centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on specialized facilities for comprehensive cancer care and the rising demand for targeted and personalized treatment approaches.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, increased prevalence of hematological disorders, and a robust regulatory framework facilitating the rapid adoption of lenalidomide. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of hematological disorders, a growing elderly population, and rising healthcare investments. For instance, Novartis International AG filed a regulatory application in November 2023 for lenalidomide plus another medication to treat multiple myeloma to gain quicker access to the market.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Lenalidomide Market Report 2023 - 2034
Lenalidomide Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- 5mg Capsules
- 10mg Capsules
- 15 mg Capsules
- 25 mg Capsules
Lenalidomide Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Multiple myeloma (MM)
- Myelodysplastic syndromes (MDS)
- Others
Lenalidomide Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Cancer Treatment Centers
- Research Institutes
Lenalidomide Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Lenalidomide Market: Type Estimates & Trend Analysis
8. Lenalidomide Market: Application Estimates & Trend Analysis
9. Lenalidomide Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Lenalidomide Market
12. Europe Global Lenalidomide Market
13. Asia Pacific Global Lenalidomide Market
14. Latin America Global Lenalidomide Market
15. MEA Global Lenalidomide Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Celgene Corporation (Acquired by Bristol Myers Squibb)
- Natco Pharma Limited
- Mylan N.V.
- Dr. Reddy's Laboratories Ltd.
- Cipla Ltd.
- Sun Pharmaceutical Industries Ltd.
- LUPIN
- Glenmark Pharmaceuticals
- Accord Healthcare
- Strides Pharma Science Limited
- Hetero Drugs Limited
- Teva Pharmaceutical Industries Ltd.
- Alkem Laboratories
- Aurobindo Pharma Ltd.
- Novartis International AG.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 10.74 Billion |
| Forecasted Market Value ( USD | $ 18.67 Billion |
| Compound Annual Growth Rate | 5.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
